Business

FDA Drug Approvals Decline by 15.44%, but Small Pharma Companies Drive Innovation

While the overall numbers have declined, smaller pharmaceutical companies are emerging as key players in the industry, contributing significantly to innovation and addressing unmet medical needs, according to a recent report by GlobalData.

• By Newsdesk
• New Delhi
• Mar 24, 2025

Business

The U.S. Food and Drug Administration (FDA) approved 126 innovator and biosimilar drugs in 2024, marking a 15.44% decrease from the 149 approvals granted in 2023. While the overall numbers have declined, smaller pharmaceutical companies are emerging as key players in the industry, contributing significantly to innovation and addressing unmet medical needs, according to a recent report by GlobalData.

The Role of Smaller Pharma in Drug Development

GlobalData’s Bio/Pharmaceutical Outsourcing report highlights the growing influence of smaller pharmaceutical companies that rely heavily on contract development and manufacturing organizations (CDMOs) to navigate the complex landscape of drug development and production. This collaboration enables these companies to access cutting-edge manufacturing technologies without the financial burden of maintaining in-house facilities.

"These companies are not only filling critical gaps in patient care but also demonstrating agility in bringing novel therapies to market," said Adam Bradbury, Pharma Analyst at GlobalData. "Through strategic partnerships with CDMOs, they overcome manufacturing challenges and scale production efficiently in a competitive market."

Notable Approvals in 2024

Several smaller pharmaceutical firms secured their first FDA approvals this year, underscoring their growing impact. Madrigal Pharmaceuticals gained approval for Rezdiffra (resmetirom), the first therapy designed to treat liver scarring caused by non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. Similarly, Verona Pharma Inc. received approval for Ohtuvayre (ensifentrine), a novel treatment for chronic obstructive pulmonary disease (COPD) in adult patients.

These breakthroughs illustrate the ability of smaller players to pioneer advancements in specialized therapeutic areas, where large pharmaceutical companies may hesitate to invest due to perceived risks.

CDMOs as Strategic Partners

The report further emphasizes the increasing reliance on CDMOs for development and manufacturing support. These organizations offer specialized expertise, regulatory compliance, and scalable production capabilities, allowing smaller firms to navigate the challenges of drug commercialization.

Additionally, the report covers trends in contract manufacturing agreements, mergers and acquisitions, financing activity, and regulatory developments. One notable update includes the European Medicines Agency’s launch of a Shortages Monitoring Platform, aimed at enhancing transparency in the pharmaceutical supply chain.

What future looks like

Despite the drop in FDA drug approvals, the resilience and innovation demonstrated by smaller pharmaceutical companies offer a promising outlook for the industry. As these companies continue to address unmet medical needs and collaborate with CDMOs, the potential for groundbreaking therapies remains strong.

With the evolving pharmaceutical landscape, stakeholders will closely watch how smaller companies navigate regulatory challenges and bring transformative treatments to market in the coming years.

For more insights into pharmaceutical outsourcing trends, GlobalData’s Bio/Pharmaceutical Outsourcing report provides comprehensive analysis and detailed updates on the industry’s latest developments.